ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 226 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q1 2023. The put-call ratio across all filers is 1.03 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $9,590 | -53.2% | 269 | -39.4% | 0.00% | -100.0% |
| Q2 2023 | $20,482 | +262.3% | 444 | +214.9% | 0.00% | – |
| Q1 2023 | $5,654 | -63.6% | 141 | -57.9% | 0.00% | -100.0% |
| Q4 2022 | $15,521 | +210.4% | 335 | +193.9% | 0.00% | – |
| Q3 2022 | $5,000 | -16.7% | 114 | +17.5% | 0.00% | – |
| Q2 2022 | $6,000 | +50.0% | 97 | +76.4% | 0.00% | – |
| Q1 2022 | $4,000 | -42.9% | 55 | -38.2% | 0.00% | – |
| Q4 2021 | $7,000 | – | 89 | +1680.0% | 0.00% | – |
| Q3 2021 | $0 | -100.0% | 5 | -28.6% | 0.00% | – |
| Q1 2021 | $1,000 | -50.0% | 7 | -75.0% | 0.00% | – |
| Q2 2019 | $2,000 | 0.0% | 28 | 0.0% | 0.00% | – |
| Q1 2019 | $2,000 | -83.3% | 28 | -90.6% | 0.00% | -100.0% |
| Q4 2018 | $12,000 | +200.0% | 298 | +547.8% | 0.00% | – |
| Q3 2018 | $4,000 | +33.3% | 46 | 0.0% | 0.00% | – |
| Q2 2018 | $3,000 | +50.0% | 46 | 0.0% | 0.00% | – |
| Q1 2018 | $2,000 | 0.0% | 46 | 0.0% | 0.00% | – |
| Q4 2017 | $2,000 | – | 46 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| EcoR1 Capital, LLC | 497,899 | $31,617,000 | 3.20% |
| HIGHLINE CAPITAL MANAGEMENT, L.P. | 390,453 | $24,794,000 | 1.81% |
| First Light Asset Management, LLC | 180,017 | $11,431,000 | 1.59% |
| Rock Springs Capital Management LP | 580,000 | $36,830,000 | 1.33% |
| Capital Impact Advisors, LLC | 36,165 | $2,244,000 | 0.82% |
| SECTOR GAMMA AS | 79,653 | $5,058,000 | 0.81% |
| Verity Asset Management, Inc. | 7,193 | $457,000 | 0.51% |
| Opus Point Partners Management, LLC | 5,064 | $322,000 | 0.48% |
| Capital International Sarl | 52,000 | $3,302,000 | 0.46% |
| PACIFIC VIEW ASSET MANAGEMENT, LLC | 6,216 | $394,000 | 0.43% |